BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 280160)

  • 1. Inhibition of adenosine deaminase by co-vidarabine and its effect on the metabolic disposition of adenine arabinoside (vidarabine).
    Borondy PE; Chang T; Maschewske E; Glazko AJ
    Ann N Y Acad Sci; 1977 Mar; 284():9-20. PubMed ID: 280160
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased toxicity of 9-beta-D-arabinofuranosyladenine in the presence of an inhibitor of adenosine deaminase.
    Plunkett W; Cohen SS
    Ann N Y Acad Sci; 1977 Mar; 284():91-102. PubMed ID: 280161
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of a novel adenosine deaminase inhibitor (co-vidarabine, co-V) upon the antiviral activity in vitro and in vivo of vidarabine (Vira-Atm) for DNA virus replication.
    Sloan BJ; Kielty JK; Miller FA
    Ann N Y Acad Sci; 1977 Mar; 284():60-80. PubMed ID: 212990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenine arabinoside inhibition of adenovirus replication enhanced by an adenosine deaminase inhibitor.
    Wigand R
    J Med Virol; 1979; 4(1):59-65. PubMed ID: 119038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral activity in the rabbit cornea of adenine arabinoside, Ara-A 5' monophosphate, and hypoxanthine arabinoside; and interactions with adenosine deaminase inhibitor.
    Falcon MG; Jones BR
    J Gen Virol; 1977 Jul; 36(1):199-202. PubMed ID: 196039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the effects of infusion of enzyme inhibitors on mouse adenosine deaminase.
    Trotta PP; Ahland MP; Brown GF; Balis ME
    Mol Pharmacol; 1978 Jan; 14(1):199-209. PubMed ID: 625284
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues.
    Plunkett W
    Ann N Y Acad Sci; 1985; 451():150-9. PubMed ID: 3907452
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of an adenosine deaminase inhibitor on the uptake and metabolism of arabinosyl adenine (Vidarabine) by intact human erythrocytes.
    Chang T; Glazko AJ
    Res Commun Chem Pathol Pharmacol; 1976 May; 14(1):127-40. PubMed ID: 935646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral activity of an adenosine deaminase inhibitor: decreased replication of herpes simplex virus.
    Williams BB; Lerner AM
    J Infect Dis; 1975 Jun; 131(6):673-7. PubMed ID: 166117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of drug metabolism by a prodrug: 9-beta-D-arabinofuranosyladenine 5'-valerate as an inhibitor of adenosine deaminase.
    Lipper RA; Machkovech SM; Drach JC; Higuchi WI
    Mol Pharmacol; 1978 Mar; 14(2):366-9. PubMed ID: 642934
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of adenosine deaminase inhibitors on the apparent rate of phosphorylation of deoxyadenosine.
    Deibel MR; Coleman MS; Hutton JJ
    Biochem Med; 1981 Jun; 25(3):288-97. PubMed ID: 6973972
    [No Abstract]   [Full Text] [Related]  

  • 12. Toxicities of adenosine and 2'-deoxyadrenosine in L cells treated with inhibitors of adenosine deaminase.
    Lapi L; Cohen SS
    Biochem Pharmacol; 1977 Jan; 26(1):71-6. PubMed ID: 299815
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Biochem Pharmacol; 1979; 28(2):201-6. PubMed ID: 426835
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of a new adenosine deaminase inhibitor, isocoformycin, on toxicity, antitumor activity and tissue distribution of formycin A and 9-beta-D-arabinofuranosyladenine.
    Hidaka T; Katayama K; Yamashita K; Yamashita T; Watanabe K; Shimazaki M; Ohno M; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1980 Mar; 33(3):303-9. PubMed ID: 7380742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbocyclic arabinosyladenine, an adenosine deaminase resistant antiviral agent.
    Vince R; Daluge S
    J Med Chem; 1977 Apr; 20(4):612-3. PubMed ID: 191615
    [No Abstract]   [Full Text] [Related]  

  • 16. Potentiation of cytotoxicity and antitumor activity of adenosine analogs by the adenosine deaminase inhibitor adecypenol.
    Tanaka H; Kawakami T; Yang ZB; Komiyama K; Omura S
    J Antibiot (Tokyo); 1989 Nov; 42(11):1722-4. PubMed ID: 2584153
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nornyl)adenine on plasma levels and urinary excretion of 9-beta-D-arabinofuranosyladenine in the mouse 1,2,3.
    Suling WJ; Rice LS; Shannon WM
    Cancer Treat Rep; 1978 Mar; 62(3):369-73. PubMed ID: 647695
    [No Abstract]   [Full Text] [Related]  

  • 18. Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors.
    Agarwal RP; Spector T; Parks RE
    Biochem Pharmacol; 1977 Mar; 26(5):359-67. PubMed ID: 849330
    [No Abstract]   [Full Text] [Related]  

  • 19. Adechlorin, a new adenosine deaminase inhibitor containing chlorine production, isolation and properties.
    Omura S; Imamura N; Kuga H; Ishikawa H; Yamazaki Y; Okano K; Kimura K; Takahashi Y; Tanaka H
    J Antibiot (Tokyo); 1985 Aug; 38(8):1008-15. PubMed ID: 3840153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of brain adenosine deaminase by 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl) adenine.
    Skolnick P; Nimitkitpaisan Y; Stalvey L; Daly JW
    J Neurochem; 1978 Jun; 30(6):1479-82. PubMed ID: 670988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.